MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
1.860
+0.250
+15.53%
Opening 11:06 03/28 EDT
OPEN
1.690
PREV CLOSE
1.610
HIGH
1.968
LOW
1.665
VOLUME
234.70K
TURNOVER
0
52 WEEK HIGH
2.840
52 WEEK LOW
0.5347
MARKET CAP
102.43M
P/E (TTM)
-0.9248
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CNTB last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CNTB last week (0311-0315)?
Weekly Report · 03/18 12:02
Weekly Report: what happened at CNTB last week (0304-0308)?
Weekly Report · 03/11 11:57
HC Wainwright & Co. Initiates Coverage of Connect Biopharma Holdings Limited - Depositary Receipt () (CNTB) with Buy Recommendation
NASDAQ · 03/05 03:31
SMR, BBAI and PHUN are among pre market gainers
On the Move SMR, BBAI and PHUN are among pre market gainers. BitFuFu (FUFU) +105%. Ainos (AIMD) +70%. Akero Therapeutics (AKRO) stock jumps as lead drug shows added fibrosis improvement in MASH patients.
Seeking Alpha · 03/04 13:34
Connect Biopharma Initiated at Buy by HC Wainwright & Co.
Dow Jones · 03/04 12:23
Connect Biopharma Price Target Announced at $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/04 12:23
HC Wainwright & Co. Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $7
Benzinga · 03/04 12:11
More
About CNTB
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the People’s Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.